Healing & RecoveryLimited ResearchResearch OnlyC

BPC-157 Stable

BPC-157 Stable Capsule

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Studies cited
5
Research grade
C
Experience
76

Overall check-ins

Activity
47

Trackers & reports

Typical Dose

Varies by protocol

Route

Oral

Cycle

Protocol-dependent

Storage

Room Temperature

What is BPC-157 Stable?

Stabilized oral BPC-157 variant marketed for GI-focused research protocols.

Research Indications

Tissue RepairMost Effective

Demonstrated acceleration of wound healing and soft tissue repair in research

Gut HealthEffective

Research shows beneficial effects on intestinal lining and GI function

Joint SupportEffective

Associated with reduced joint inflammation and improved mobility

Muscle RecoveryModerate

May support faster recovery from muscle strains and exercise stress

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting Dose100 mcgOnce dailySubcutaneous injection
Standard Dose250 mcgOnce dailySubcutaneous injection

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

TB-500 / BPC-157 (stack)Compatible
NSAIDs (Ibuprofen, Naproxen)Caution
CorticosteroidsCaution
AnticoagulantsMonitor
GH SecretagoguesCompatible
NAD+Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove BPC-157 Stable vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.

Week 2–4

Improved tissue mobility and reduced discomfort. Early healing acceleration.

Week 4–8

Significant recovery milestones. Stronger tissue repair and functional improvement.

Week 8–12

Near-complete healing in many cases. Improved strength and tissue integrity.

Side Effects & Safety

  • Generally well-tolerated in research settings
  • Mild nausea with higher doses
  • Injection site redness or discomfort
  • Rare: Dizziness or lightheadedness
  • Potential effect on blood pressure (monitor if hypertensive)

BPC-157 Stable is not FDA-approved and cannot be prepared by 503A compounding pharmacies. PeptIQ does not sell peptides or list vendors. Talk with a licensed clinician.

FDA Status & Regulatory Info

Research Only

Stabilized oral BPC-157 variant marketed for GI-focused research protocols.

Rx Required: No
503A Ban: Yes
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 669 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

669 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 63% · Mixed 20% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
24
Digestive comfort
58
Skin appearance
152
Appetite control
29
Energy
126

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
120
Flushing
138
Headache
117
GI discomfort
25
Dizziness
126

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 400–600 mcg

Reports span 50–1000 mcg

50–100
6
100–200
10
200–400
16
400–600
17
600–1000
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing33stacking41side effects29bpc-157 stable27

How repeat users are trending

Among repeat reporters, 58% said they felt similar to their last entry, 43% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 17 days · Based on 147 repeat reporters

Share Your Experience

Rate BPC-157 Stable in the PeptIQ app and help the community make informed decisions.

Research References (4)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  3. PubMed

    Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

    Seiwerth S, Milavic M, Vukojevic J, et al. Frontiers in pharmacology. 2021

    Source
    Wiki study page →
  4. PubMed

    Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy

    Sikiric P, Drmic D, Sever M, et al. Current pharmaceutical design. 2020

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for BPC-157 Stable.

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your BPC-157 Stable protocol in PeptIQ

Turn this BPC-157 Stable guide into a living protocol — doses, vials, and history in one place.

Track BPC-157 StableOpen web app

iOS, Android, and web

Research supplier

BPC-157 listings are for laboratory / research use only — not for human consumption.

Research use only. Partner link. PeptIQ may earn a referral fee. Not medical advice.

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Route
Oral
Availability
Research only
Rx Required
No
503A Ban
Yes
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss BPC-157 Stable with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for BPC-157 Stable.